(Q39658505)

13 September 2017

title

Effect of Immune Complex Formation on the Distribution of a Novel Antibody to the Ovarian Tumor Antigen CA125 (English)

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

8 July 2024

author name string

William Mallet

2

1 reference

13 September 2017

Suzanna Clark

3

1 reference

13 September 2017

Margaret Kenrick

4

1 reference

13 September 2017

Mohammed Majidy

5

1 reference

13 September 2017

Michelle Schweiger

6

1 reference

13 September 2017

Marjie Van Hoy

7

1 reference

13 September 2017

Siao Ping Tsai

8

1 reference

13 September 2017

Gregory Bennett

9

1 reference

13 September 2017

Ben-Quan Shen

10

1 reference

13 September 2017

Sarajane Ross

11

1 reference

13 September 2017

Paul Fielder

12

1 reference

13 September 2017

Leslie Khawli

13

1 reference

13 September 2017

Jay Tibbitts

14

1 reference

13 September 2017

Cinthia V. Pastuskovas

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20823292

8 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20823292

8 July 2024

publication date

7 September 2010

1 reference

full work available at URL

13 September 2017

http://intl-dmd.aspetjournals.org/cgi/content/abstract/38/12/2309

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20823292

https://syndication.highwire.org/content/doi/10.1124/dmd.110.034330

8 July 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Drug Metabolism and Disposition

8 July 2024

published in

1 reference

13 September 2017

volume

38

1 reference

13 September 2017

issue

12

1 reference

13 September 2017

page(s)

2309-2319

1 reference

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

13 September 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

CA 125: the past and the future

8 July 2024

3

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

CA 125 production and release by ovarian cancer cells in vitro

8 July 2024

4

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer

8 July 2024

5

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer

8 July 2024

6

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Precision of measurement of tissue concentrations by RLG

8 July 2024

7

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models

8 July 2024

8

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

The effect of circulating antigen on the biodistribution of the engineered human antibody hCTM01 in a nude mice model.

8 July 2024

9

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer

8 July 2024

10

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Antibody-antigen complex formation following injection of OC125 monoclonal antibody in patients with ovarian cancer.

8 July 2024

12

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Monoclonal antibodies as therapeutic agents for cancer

8 July 2024

13

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

8 July 2024

15

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

A human/mouse chimeric monoclonal antibody against CA125 for radioimmunoimaging of ovarian cancer

8 July 2024

16

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16)

8 July 2024

17

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Pharmacokinetics and radiation dosimetry of 99Tcm-labelled monoclonal antibody B43.13 in ovarian cancer patients

8 July 2024

18

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Monoclonal antibody therapy of ovarian cancer

8 July 2024

19

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo

8 July 2024

20

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

The CA 125 gene: an extracellular superstructure dominated by repeat sequences

8 July 2024

21

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Circulating antigen: bad or good for immunoscintigraphy?

8 July 2024

22

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Influence of circulating antigen on the biodistribution and tumour localization of radiolabelled monoclonal antibody in a human tumour: nude mouse xenograft model

8 July 2024

23

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Epidemiology and etiology of ovarian cancer

8 July 2024

24

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Arming antibodies for cancer therapy

8 July 2024

25

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

A novel quantitative method for determining the biodistribution of radiolabeled xenobiotics using whole-body cryosectioning and autoradioluminography

8 July 2024

26

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Quantitative comparison of autoradioluminographic and radiometric tissue distribution studies using carbon-14 labeled xenobiotics

8 July 2024

27

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01

8 July 2024

28

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Effect of circulating antigen on immunoscintigraphy of ovarian cancer patients using anti-CA125 monoclonal antibody.

8 July 2024

30

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1).

8 July 2024

31

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Quantitative distribution studies in animals: cross-validation of radioluminography versus liquid-scintillation measurement

8 July 2024

32

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Monoclonal antibody drug immunoconjugates for targeted treatment of cancer

8 July 2024

33

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Whole-body autoradiography

8 July 2024

34

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

CA 125: fundamental and clinical aspects

8 July 2024

35

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Arming antibodies: prospects and challenges for immunoconjugates

8 July 2024

36

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16.

8 July 2024

37

1 reference

https://api.crossref.org/works/10.1124/DMD.110.034330

8 July 2024

Identifiers

1 reference

13 September 2017

1 reference